For left-sided RAS/BRAF wild-type colorectal cancers, they found no difference in the rate of liver resection or progression-free survival when combining doublet chemotherapy with an anti-epidermal growth factor receptor (EGFR) antibody or an anti-vascular endothelial growth factor antibody (VEGF). This evidence concerns the gene EGFR and colorectal cancer.